Loop diuretics in heart failure

被引:0
作者
G. Michael Felker
机构
[1] Duke Clinical Research Institute,Divisions of Cardiology and Clinical Pharmacology
[2] Duke University School of Medicine,undefined
来源
Heart Failure Reviews | 2012年 / 17卷
关键词
Heart failure; Diuretics; Congestion; Clinical trials;
D O I
暂无
中图分类号
学科分类号
摘要
Congestion is a major component of the clinical syndrome of heart failure, and diuretic therapy remains the cornerstone of congestion management. Despite being widely used, there is very limited evidence from prospective randomized studies to guide the prescription and titration of diuretics. A thorough understanding of the pharmacology of loop diuretics is crucial to the optimal use of these agents. Although multiple observational studies have suggested that high doses of diuretics may be harmful, all such analyses are confounded by the association of higher diuretic doses with greater severity of illness and comorbidity. Recent data from randomized trials suggest that higher doses of diuretics may be more effective at relieving congestion and that associated changes in renal function are typically transient. Data from other ongoing trials will continue to inform our understanding of the optimal role for loop diuretics in the treatment of heart failure.
引用
收藏
页码:305 / 311
页数:6
相关论文
共 333 条
  • [1] Gheorghiade M(2010)Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine Eur J Heart Fail 12 423-433
  • [2] Follath F(2004)Searching for evidence: refractory questions in advanced heart failure J Card Fail 10 210-218
  • [3] Ponikowski P(2006)HFSA 2006 comprehensive heart failure practice guideline J Card Fail 12 1-119
  • [4] Barsuk JH(2009)2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 1977-2016
  • [5] Blair JEA(2008)ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J 29 2388-2442
  • [6] Cleland JG(1990)Comparison of neuroendocrine activation in patients with left-ventricular dysfunction with and without congestive-heart-failure—a substudy of the studies of left-ventricular dysfunction (SOLVD) Circulation 82 1724-1729
  • [7] Dickstein K(1985)Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart-failure–activation of the neurohumoral axis Ann Intern Med 103 1-6
  • [8] Drazner MH(2001)Diuretic therapy and resistance in congestive heart failure Cardiology 96 132-143
  • [9] Fonarow GC(1995)Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure[ast] Clin Pharmacol Ther 57 601-609
  • [10] Jaarsma T(2001)Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure Am J Med 111 513-520